Case Page

 

Case Status:    ONGOING    
On or around 11/01/2017 (Ongoing date of last review)

Filing Date: August 21, 2017

According to the law firm press release, Teva develops, manufactures, markets, and distributes generic medicines. The Complaint alleges that during the Class Period, defendants issued materially false and misleading statements and/or failed to disclose adverse information regarding Teva's business and outlook. Specifically, the Complaint alleges that the poor performance of its U.S. generics business resulted in Teva's recording a goodwill impairment charge related to the acquisition of Actavis Generics and was a key factor in cutting Teva's dividend by 75%.

COMPANY INFORMATION:

Sector: Healthcare
Industry: Major Drugs
Headquarters: Israel

SECURITIES INFORMATION:

Ticker Symbol: TEVA
Company Market: New York SE
Market Status: Public (Listed)

About the Company & Securities Data


"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
COURT: E.D. Pennsylvania
DOCKET #: 17-CV-03743
JUDGE: Hon. PAUL S. DIAMOND
DATE FILED: 08/21/2017
CLASS PERIOD START: 11/15/2016
CLASS PERIOD END: 08/02/2017
PLAINTIFF FIRMS NAMED IN COMPLAINT:
  1. Kaufman, Coren & Ress, P.C.
    Two Commerce Square, Suite 3900 , Kaufman, Coren & Ress, P.C., PA 19103
    215-735-8700 ·
No Document Title Filing Date